Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369	NDA	Biogen MA Inc.	64406-029-01	1 BOTTLE in 1 CARTON (64406-029-01) / 14 CAPSULE in 1 BOTTLE	2023-10-31
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369	NDA	Biogen MA Inc.	64406-030-01	1 BOTTLE in 1 CARTON (64406-030-01) / 14 CAPSULE in 1 BOTTLE	2023-10-31
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369	NDA	Biogen MA Inc.	64406-030-02	1 CARTON in 1 CARTON (64406-030-02) / 1 BLISTER PACK in 1 CARTON / 28 CAPSULE in 1 BLISTER PACK	2023-10-31
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369	NDA	Biogen MA Inc.	64406-031-01	1 BOTTLE in 1 CARTON (64406-031-01) / 14 CAPSULE in 1 BOTTLE	2023-10-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

ZURZUVAE, the first oral treatment approved for postpartum depression (PPD), presents a developing supply chain landscape. The active pharmaceutical ingredient (API) is zuranolone, a neuroactive steroid. Manufacturers rely on a network of chemical suppliers for raw materials, intermediates, and the finished API. Identifying these suppliers is crucial for assessing supply chain resilience, potential cost drivers, and competitive dynamics.

Who are the Key Suppliers of Zuranolone API?

The primary manufacturer of ZURZUVAE is Sage Therapeutics. Sage Therapeutics is responsible for the synthesis and production of the zuranolone API. While Sage Therapeutics manufactures the API, its production relies on a series of upstream chemical suppliers providing necessary reagents and intermediates. The specific entities contracted by Sage Therapeutics for these upstream materials are not always publicly disclosed, representing a key area of supply chain opacity.

However, typical pharmaceutical API synthesis involves a multi-step process requiring specialized chemical manufacturing capabilities. Companies that typically provide such services include:

Contract Development and Manufacturing Organizations (CDMOs): These organizations specialize in the outsourced development and manufacturing of pharmaceutical ingredients and finished drug products. Companies like Lonza, Catalent, and Thermo Fisher Scientific (Patheon) are major players in this sector and could be involved in various stages of zuranolone production, from intermediate synthesis to final API manufacturing.
Specialty Chemical Manufacturers: These companies produce specific chemical compounds used as building blocks or reagents in complex synthesis pathways. The exact chemical intermediates required for zuranolone synthesis are proprietary, but would necessitate suppliers with expertise in steroidal chemistry or related fields.

The exact identity and number of direct suppliers for zuranolone API to Sage Therapeutics are proprietary. This information is generally not disclosed for competitive and security reasons.

What are the Critical Raw Materials and Intermediates for Zuranolone Synthesis?

The synthesis of zuranolone, a neuroactive steroid, involves a complex chemical pathway. While the precise proprietary synthesis route used by Sage Therapeutics is not public, the general classes of raw materials and intermediates required for steroid synthesis are well-established. These include:

Steroid Precursors: The synthesis of a steroid like zuranolone likely begins with naturally occurring or synthetically derived steroid scaffolds. Cholesterol or diosgenin are common starting points for many steroid syntheses. Companies that process these natural products or synthesize steroid backbones would be upstream suppliers.
Reagents and Catalysts: A wide array of chemical reagents and catalysts are essential for specific chemical transformations, such as oxidation, reduction, halogenation, and functional group modifications. These can include organometallic compounds, oxidizing agents (e.g., chromium-based reagents, peroxides), reducing agents (e.g., metal hydrides), acids, bases, and various specialized catalysts.
Solvents: Pharmaceutical synthesis requires significant quantities of high-purity solvents for reactions, extractions, and purifications. Common solvents include alcohols (methanol, ethanol, isopropanol), ethers (diethyl ether, tetrahydrofuran), hydrocarbons (hexane, toluene), and chlorinated solvents (dichloromethane).
Protecting Groups and Deprotecting Agents: To selectively modify specific functional groups within a complex molecule, chemists often employ temporary protecting groups. Reagents for adding and removing these groups are also critical.
Chiral Synthesis Reagents: Zuranolone is a chiral molecule, meaning it has specific stereochemistry. The synthesis may involve chiral catalysts, auxiliaries, or reagents to ensure the production of the desired enantiomer.

The supply of these materials involves a global network of chemical producers. Key considerations for these upstream suppliers include:

Quality and Purity: Pharmaceutical manufacturing demands exceptionally high purity standards for all raw materials and intermediates to ensure the safety and efficacy of the final drug product.
Regulatory Compliance: Suppliers must adhere to Good Manufacturing Practices (GMP) and other relevant regulatory guidelines.
Scalability: As demand for ZURZUVAE grows, suppliers must demonstrate the capacity to scale up production to meet Sage Therapeutics' needs.

Specific companies involved in supplying these raw materials are difficult to pinpoint without direct disclosure from Sage Therapeutics, as these are often standard chemical commodities or proprietary intermediates. However, major global chemical companies that produce bulk chemicals, fine chemicals, and custom synthesis services would be potential sources.

What is Sage Therapeutics' Role in ZURZUVAE Production?

Sage Therapeutics holds the primary responsibility for the development, manufacturing, and commercialization of ZURZUVAE. Its role encompasses several critical functions:

Drug Discovery and Development: Sage Therapeutics conducted the research and clinical trials that led to the approval of zuranolone for PPD.
API Synthesis and Manufacturing: Sage Therapeutics is responsible for the in-house or contracted manufacturing of the zuranolone API. This involves developing and optimizing the synthesis process to ensure consistent quality, yield, and cost-effectiveness.
Formulation and Finished Drug Product Manufacturing: Sage Therapeutics oversees the formulation of the API into the final ZURZUVAE capsules and the manufacturing of these finished dosage forms. This can be done internally or through contract manufacturing organizations (CMOs).
Supply Chain Management: Sage Therapeutics manages its entire supply chain, from sourcing raw materials and intermediates to distributing the finished drug product to the market. This includes qualifying suppliers, ensuring regulatory compliance, and mitigating supply chain risks.
Regulatory Filings and Approvals: Sage Therapeutics is responsible for all interactions with regulatory agencies, including submitting New Drug Applications (NDAs) and obtaining marketing authorizations.
Commercialization and Distribution: Sage Therapeutics manages the sales, marketing, and distribution of ZURZUVAE to pharmacies and healthcare providers.

In March 2024, Biogen entered into an agreement with Sage Therapeutics to co-commercialize ZURZUVAE in the United States and Canada. Under this agreement, Biogen will share in commercialization costs and profits. This partnership influences the commercial supply chain but not the fundamental API manufacturing process, which remains under Sage Therapeutics' purview.

What are the Regulatory Considerations for ZURZUVAE Suppliers?

Suppliers involved in the ZURZUVAE supply chain, particularly those providing raw materials, intermediates, and the API, are subject to stringent regulatory oversight. Key considerations include:

Good Manufacturing Practices (GMP): All facilities involved in the manufacturing of APIs and drug products must comply with GMP regulations. This ensures that products are consistently produced and controlled according to quality standards. For API suppliers, this typically means adhering to ICH Q7 guidelines for GMP for Active Pharmaceutical Ingredients.
Facility Inspections: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), conduct inspections of manufacturing facilities to verify compliance with GMP.
Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory agencies. A DMF is a submission to the FDA or other regulatory bodies that contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review proprietary manufacturing information without disclosing it to the drug product applicant.
Traceability and Quality Control: Suppliers must maintain robust quality control systems and ensure the traceability of all materials from origin to delivery. This includes comprehensive testing of raw materials and intermediates to confirm identity, purity, and quality.
Change Control: Any changes to manufacturing processes, materials, or facilities must be managed through a formal change control system and, if necessary, reported to regulatory authorities and the drug product applicant (Sage Therapeutics).
Supply Chain Security and Audits: Regulatory agencies and pharmaceutical companies conduct audits of their suppliers to assess compliance and identify potential risks. This includes evaluating the supplier's quality management systems, operational controls, and security measures.
Impurity Profiling: Suppliers must provide detailed information on potential impurities in their materials, including their origin and levels. This is critical for the final drug product's safety assessment.

The regulatory landscape for pharmaceutical suppliers is designed to ensure the quality, safety, and efficacy of medicines. For ZURZUVAE, compliance with these regulations by all supply chain partners is non-negotiable.

What are the Potential Supply Chain Risks for ZURZUVAE?

The supply chain for a novel pharmaceutical like ZURZUVAE, particularly one with a complex API synthesis, faces several potential risks:

Single Sourcing: If Sage Therapeutics relies on a single supplier for a critical intermediate or the API itself, any disruption at that supplier (e.g., manufacturing issue, natural disaster, geopolitical event) could halt production.
Geopolitical Instability: Many raw materials and chemical intermediates are sourced globally. Political instability, trade wars, or export restrictions in key manufacturing regions can disrupt supply.
Raw Material Availability and Price Volatility: The availability and cost of precursor chemicals and reagents can fluctuate based on global supply and demand, energy prices, and environmental regulations.
Quality Control Failures: A lapse in quality control by an upstream supplier can lead to the rejection of batches, production delays, and potentially the need to recall finished products if undetected.
Regulatory Non-Compliance: A supplier failing to meet GMP or other regulatory standards can result in forced shutdowns, penalties, and a loss of approved status, directly impacting the ZURZUVAE supply.
Intellectual Property and Confidentiality Breaches: The proprietary nature of the zuranolone synthesis means that breaches of confidentiality or intellectual property theft by suppliers could have significant business implications.
Logistical Challenges: Transportation disruptions, customs delays, and specialized handling requirements for certain chemicals can all impact the timely delivery of materials.
Scalability Issues: If demand for ZURZUVAE significantly outpaces production capacity, upstream suppliers may struggle to scale up their operations quickly enough, leading to shortages.
Natural Disasters and Pandemics: Unforeseen events like earthquakes, floods, or global health crises can cripple manufacturing and logistics networks, affecting component availability.

Sage Therapeutics' robust supply chain management, including supplier diversification where feasible, rigorous qualification processes, and contingency planning, is crucial for mitigating these risks. The partnership with Biogen for commercialization also introduces a shared responsibility for supply chain oversight in the U.S. and Canada.

How does the Partnership with Biogen Impact ZURZUVAE Supply?

The co-commercialization agreement between Sage Therapeutics and Biogen for ZURZUVAE in the U.S. and Canada, announced in March 2024, primarily impacts the commercial distribution and market access aspects of the supply chain, rather than the core API manufacturing. Key impacts include:

Shared Commercialization Responsibilities: Biogen will contribute to the marketing, sales, and distribution efforts. This means Biogen's established commercial infrastructure and sales force will be leveraged to promote and distribute ZURZUVAE.
Supply Chain Coordination: While Sage Therapeutics remains responsible for API manufacturing and finished product supply, the co-commercialization necessitates close coordination on forecasting, inventory management, and distribution logistics between the two companies to ensure product availability in the designated markets.
Potential for Expanded Reach: Biogen's global presence and established market relationships could facilitate broader access to ZURZUVAE in the future, potentially influencing global supply chain planning and expansion.
Financial Risk Sharing: The agreement involves sharing commercialization costs and profits, which indirectly affects the financial resources available for supply chain investments and capacity expansion.
Operational Integration: Establishing seamless integration between Sage Therapeutics' manufacturing and supply chain operations and Biogen's commercial operations is critical for efficient product flow from manufacturing site to patient.

The fundamental API synthesis and upstream chemical supply chain for zuranolone remain under Sage Therapeutics' direct control. Biogen's involvement is focused on the downstream commercialization and distribution within specific geographic regions. This partnership aims to accelerate ZURZUVAE's market penetration and ensure broader patient access.

Key Takeaways

Sage Therapeutics is the primary manufacturer of ZURZUVAE and the zuranolone API.
The synthesis of zuranolone relies on a complex chain of chemical suppliers for steroid precursors, reagents, catalysts, and solvents. Specific suppliers are proprietary.
Regulatory compliance, particularly GMP, is paramount for all entities within the ZURZUVAE supply chain.
Potential supply chain risks include single sourcing, geopolitical instability, raw material volatility, and quality control failures.
The co-commercialization agreement with Biogen impacts distribution and market access in the U.S. and Canada, not core API manufacturing.

FAQs

Is ZURZUVAE manufactured in the United States? The specific locations of Sage Therapeutics' API manufacturing and finished drug product manufacturing facilities are not publicly detailed, but pharmaceutical production can occur globally. Regulatory filings would indicate the jurisdiction where manufacturing is conducted.
Are there any generic versions of ZURZUVAE currently available? As ZURZUVAE is a newly approved drug with patent protection, generic versions are not currently available. Generic competition typically arises after patent expiry.
How does Sage Therapeutics ensure the quality of its raw materials? Sage Therapeutics employs rigorous supplier qualification processes, conducts regular audits, and performs stringent quality control testing on all incoming raw materials and intermediates to ensure they meet required specifications.
What is the typical lead time for ordering specialized pharmaceutical chemicals? Lead times for specialized pharmaceutical chemicals can vary significantly, ranging from several weeks to many months, depending on the complexity of the synthesis, the availability of raw materials, and the supplier's production schedule.
Can Biogen directly influence the manufacturing process of the zuranolone API? Under the co-commercialization agreement, Biogen's primary role is in commercialization and distribution. Sage Therapeutics retains responsibility for the manufacturing of the zuranolone API. Biogen would be involved in supply chain forecasting and coordination for the markets they co-commercialize.

Citations

[1] Sage Therapeutics. (n.d.). Sage Therapeutics and Biogen Announce Strategic Collaboration to Co-Develop and Co-Commercialize ZURZUVAE™ (zuranolone) in the United States and Canada. Retrieved from [Sage Therapeutics Press Release, March 4, 2024] (Note: Actual URL would be inserted here if publicly accessible). [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs—Substantial Changes to a Previously Approved Drug Product. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.

Suppliers and packagers for ZURZUVAE

ZURZUVAE

ZURZUVAE SUPPLIER LANDSCAPE